← FDA Drug Approvals (Drugs@FDA)

DOLUTEGRAVIR LAMIVUDINE TENOFOVIR ALAFENAMIDE

NDA · New Drug Application · Sponsor: CIPLA USA INC. · Approved 2022-03-30

Drug application

FDA Application #

NDA212527

Application type

New Drug Application

Brand name

DOLUTEGRAVIR LAMIVUDINE TENOFOVIR ALAFENAMIDE

Generic name

Dolutegravir Lamivudine Tenofovir Alafenamide

Active ingredients

DOLUTEGRAVIR LAMIVUDINE TENOFOVIR ALAFENAMIDE

Dosage form

TABLET

Route

—

Marketing status

None (Tentative Approval)

Sponsor

CIPLA USA INC.

First approval

2022-03-30

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown